Variant Gene Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs121913500
rs121913500
0.030 GeneticVariation BEFREE IDH1(R132H) mutation causes a less aggressive phenotype and radiosensitizes human malignant glioma cells independent of the oxygenation status. 26328938

2016

dbSNP: rs121913500
rs121913500
0.030 GeneticVariation BEFREE Of 158 tumors with sufficient tissue, 110 (70 %) showed nuclear cMYC immunopositivity--most frequent (95 %, χ(2) p = 0.0248) and intense (mean 1.33, ANOVA p = 0.0179) in anaplastic astrocytomas versus glioblastomas (63 %) or low grade gliomas (74 %). cMYC expression associated with younger age as well as p53 immunopositivity (OR = 3.6, p = 0.0332) and mutant IDH1 (R132H) (OR = 7.4, p = 0.06) among malignant gliomas in our cohort. 23934175

2014

dbSNP: rs121913500
rs121913500
0.030 GeneticVariation BEFREE We highlight the importance of Sox11 expression as a favourable prognosticator in glioblastomas. c-Met/nestin/IDH1-R132H expression phenotypes recapitulate the molecular subgroups of malignant glioma. 23619925

2013

dbSNP: rs12917
rs12917
0.010 GeneticVariation BEFREE This study aims to investigate the associations of O<sup>6</sup>-methylguanine-DNA methyltransferase (MGMT) genetic polymorphisms (Leu84Phe and Ile143Val) with temozolomide (TMZ) resistance and prognosis of patients with malignant gliomas. 28409559

2018

dbSNP: rs1424913115
rs1424913115
0.010 GeneticVariation BEFREE This study aims to investigate the associations of O<sup>6</sup>-methylguanine-DNA methyltransferase (MGMT) genetic polymorphisms (Leu84Phe and Ile143Val) with temozolomide (TMZ) resistance and prognosis of patients with malignant gliomas. 28409559

2018

dbSNP: rs2308321
rs2308321
0.010 GeneticVariation BEFREE This study aims to investigate the associations of O<sup>6</sup>-methylguanine-DNA methyltransferase (MGMT) genetic polymorphisms (Leu84Phe and Ile143Val) with temozolomide (TMZ) resistance and prognosis of patients with malignant gliomas. 28409559

2018

dbSNP: rs1217691063
rs1217691063
0.010 GeneticVariation BEFREE ACE I/D sequence variants but not MTHFR C677T, is strongly linked to malignant glioma risk and its variant DD genotype may act as a promising predictive biomarker for overall survival of glioma patients. 29017962

2017

dbSNP: rs12435998
rs12435998
0.010 GeneticVariation BEFREE The SNP rs12435998 was prevalent in anaplastic and malignant gliomas, and in meningiomas of all histologic grades, but unrelated to brain tumor risks. 25948789

2016

dbSNP: rs55819519
rs55819519
0.010 GeneticVariation BEFREE Of 158 tumors with sufficient tissue, 110 (70 %) showed nuclear cMYC immunopositivity--most frequent (95 %, χ(2) p = 0.0248) and intense (mean 1.33, ANOVA p = 0.0179) in anaplastic astrocytomas versus glioblastomas (63 %) or low grade gliomas (74 %). cMYC expression associated with younger age as well as p53 immunopositivity (OR = 3.6, p = 0.0332) and mutant IDH1 (R132H) (OR = 7.4, p = 0.06) among malignant gliomas in our cohort. 23934175

2014

dbSNP: rs11554137
rs11554137
0.010 GeneticVariation BEFREE Prognostic impact of the isocitrate dehydrogenase 1 single-nucleotide polymorphism rs11554137 in malignant gliomas. 23184331

2013

dbSNP: rs397515294
rs397515294
0.010 GeneticVariation BEFREE We highlight the importance of Sox11 expression as a favourable prognosticator in glioblastomas. c-Met/nestin/IDH1-R132H expression phenotypes recapitulate the molecular subgroups of malignant glioma. 23619925

2013

dbSNP: rs121912665
rs121912665
0.010 GeneticVariation BEFREE Accumulation of mutant p53(V143A) modulates the growth, clonogenicity, and radiochemosensitivity of malignant glioma cells independent of endogenous p53 status. 10585266

2000

dbSNP: rs753771086
rs753771086
0.010 GeneticVariation BEFREE Accumulation of mutant p53(V143A) modulates the growth, clonogenicity, and radiochemosensitivity of malignant glioma cells independent of endogenous p53 status. 10585266

2000